Published in Vaccine Weekly, September 30th, 2009
NPC-1C is derived from a colorectal cancer vaccine that had previously demonstrated safety and clinical activity in prior human studies. NPC-1C is a novel, monoclonal antibody intended for the treatment of advanced pancreatic and colorectal cancer.
This first human trial will evaluate the safety of NPC-1C in patients with late stage pancreatic or colorectal cancer. Anti-tumor activity has been demonstrated in both in-vitro...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly